 |
|
UCLA neuroscience research leads to a possible treatment for type 1 diabetes
September 18, 2006A new vaccine being tested in a human clinical trial holds a great deal of promise for treating type 1 diabetes, a disease that newly afflicts 35,000 children each year. The research that established the foundation for this vaccine was conducted in UCLA research laboratories. The drug is still being tested and is not likely to be available for at least a few years.
"It's the only thing so far that really slows this disease down without adverse side effects," Allan J. Tobin, a UCLA professor emeritus of physiological science and neurology, said about the new drug. "The amazing thing about this emerging story, however, is that it started from basic research on the brain." Tobin, whose laboratory conducted critical neuroscience research in the late 1980s and 1990s, is a member and former director of UCLA's Brain Research Institute.
Type 1 diabetes - also known as insulin-dependent diabetes or juvenile diabetes (because it usually begins in childhood or adolescence) - afflicts more than 1 million Americans. It is characterized by a failure of the body to produce insulin because the immune system attacks and destroys the body's insulin-producing cells of the pancreas.
On Sunday, Sept. 17, at a meeting in Copenhagen of the European Association for the Study of Diabetes, Johnny Ludvigsson - pediatrics professor at Sweden's University Hospital, Linköping University - will present results from the phase II study conducted in eight hospitals in Sweden in collaboration with Diamyd Medical (www.diamyd.com), a life science company located in Stockholm, Sweden.
This fundamental discovery that influenced thinking about diabetes was made in the Life Sciences Division of UCLA's College of Letters and Science, said Arthur P. Arnold, UCLA professor and chair of physiological science.
"The broad insight of a basic neuroscience team eventually bore fruit in the fight against this disease," Arnold said. In the 1980s, using newly developed recombinant DNA techniques, Tobin's laboratory was studying genes involved in brain development and function. Tobin's team included graduate student Daniel Kaufman, now a UCLA professor in the department of molecular and medical pharmacology, and graduate student Mark Erlander, now executive vice president and chief scientific officer of AviaraDx, a biotechnology company in Carlsbad, Calif.
Together, Kaufman and Erlander were the first to isolate the genes encoding GAD (glutamic acid decarboxylase) which is an important enzyme because it synthesizes one of the main neurotransmitters for communication between neurons. Tobin's laboratory used these tools to study neuronal development in the brain. What no one knew at that time was that GAD was also made in the cells that made insulin in the pancreas - cells that use the chemical transmitter made by GAD to communicate with other pancreas cells to help control glucose levels in the blood.
A year later, Kaufman's car fortuitously broke down while he was a postdoctoral scholar at the Salk Institute in San Diego, Calif. Forced to wait, he went to the library and stumbled on a report in a medical journal showing a connection between autoimmunity to an unknown protein in insulin-producing cells and diabetes. Kaufman surmised that this unknown protein was in fact GAD, the protein he had studied in Tobin's lab.
To study the possible connection between GAD and diabetes, Kaufman again worked with Tobin and Erlander, using the research tools they had developed to test whether autoantibodies against GAD could be found in frozen blood samples taken from individuals before they developed type 1 diabetes. They found that they could detect autoantibodies against GAD years before the symptoms of diabetes appeared.
In type 1 diabetes, the immune system destroys the insulin-producing cells slowly, over as many as seven years before any symptoms appear, Tobin said. "These tools allowed us to detect the early appearance of an autoimmune reaction more than five years before the onset of diabetes," Tobin said.
Many laboratories throughout the world are now using recombinant GAD to determine whether individuals have autoantibodies to GAD and are likely to develop diabetes. This pre-diagnostic test will be invaluable for preventing diabetes - but first, there must be a therapeutic to slow the progression of the disease.
In his own laboratory at UCLA, Kaufman, along with UCLA's Jide Tian, Michael Clare-Salzler, Eli Sercarz, Paul Lehmann and Tobin, searched for ways to "tolerize" the immune system of diabetes-prone mice to the GAD protein before the autoimmune attack began. The team reported in the journal Nature in 1993 that when young, diabetes-prone mice were treated with a small amount of the GAD protein, their immune systems learned to tolerate the protein. The autoimmune response that leads to type 1 diabetes never developed in these mice as they grew older.
Next, Kaufman and Tian developed the GAD vaccine that was able to inhibit the autoimmune response after it had already begun to attack the insulin producing cells. Kaufman and Tian showed in a study they published in Nature-Medicine in 1996 that, even after the type 1 diabetes disease process had started in diabetes-prone mice, its progression could be inhibited by the GAD vaccine.
The GAD vaccine activated T-cells that recognized GAD, Kaufman and Tian reported. "The T-cells traveled to the pancreas and, recognizing the GAD protein in the insulin-producing cells there, released calming substances called 'anti-inflammatory' cytokines, which suppressed the immune cells that were killing the insulin-producing cells," Tian explained.
UCLA licensed the technology to Diamyd Medical for clinical development. Tobin and Kaufman both serve on the scientific advisory board of Diamyd.
Based on the success of the GAD vaccine to prevent diabetes in mice, Diamyd Medical conducted a phase II clinical trial by treating adults who recently had been diagnosed with diabetes. The results showed that treatment with the GAD vaccine could preserve some insulin production for at least two years after the onset of the disease in adults.
Given these promising results, Diamyd next conducted a larger double-blind clinical trial of the GAD vaccine in 70 children and adolescents who were newly diagnosed with diabetes. After treating new diabetics with the GAD vaccine, or a placebo, the patients were followed for 15 months, without the clinicians knowing which treatment the patients had received. This month Diamyd Medical broke the code and announced that the GAD vaccine demonstrated statistically significant efficacy in preserving insulin production and that no serious adverse events associated with the therapy were observed.
Tobin and Kaufman are optimistic about the drug, which is called Diamyd, but both said it is likely to be at least a few years before a drug for type 1 diabetes is available.
"If the result holds up in a phase III trial, it's going to make a big difference," Tobin said. "It feels terrific."
"It's tremendously gratifying to see our work go from the lab to a clinical application, with the potential to help so many people," Kaufman said. "The data are very strong, and are convincing even to scientists who were initially skeptical. The vaccine is highly targeted; it activates only the immune cells that recognize GAD, which then suppresses the immune cells that are attacking the insulin-producing cells. Most of us who go into science hope our research will advance medical treatment and improve human lives; it's great news."
He added, "Such long-term preservation of insulin production after the onset of diabetes is quite remarkable. Preserving insulin-production is crucial for delaying the complications associated with long-term diabetes, such as kidney and heart disease, and neuropathy. Now that the vaccine has shown efficacy in preserving insulin production after disease onset, we are anxious to see whether the vaccine can also prevent the development of type 1 diabetes."
The children who are likely to develop type 1 diabetes can be identified by screening for autoantibodies to GAD in their blood, Kaufman said. Tobin, 64, is currently managing director of MRSSI, which advises two nonprofit organizations, the High Q Foundation and CHDI, both dedicated to finding therapies for Huntington's disease. From 1975 to 2003, he was on the faculty of UCLA, where he taught introductory biology and neuroscience. He is the coauthor of "Asking About Life," a prize-winning biology textbook whose premise is that questions are more important than answers.
Tobin's research was funded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health. Kaufman's research is funded by the National Institute of Diabetes & Digestive & Kidney Diseases, also part of part of the National Institutes of Health.
Tobin recalls bringing the excitement of his research into the UCLA classes he taught.
"When I taught the introductory biology course, I said here's the standard stuff about the immune system, but let me tell you about something that just happened in my lab," Tobin recalled. "There's a thrill of discovery, and also a sense that there remain challenges ahead; science isn't just learning a set of facts but learning how to approach and formulate scientific problems. That engagement really serves undergraduates at UCLA very differently from undergraduates at non-research colleges."
As is often true in science, solutions to important problems come from unexpected places, and basic research provides the foundation for future applications.
"Type 1 diabetes never occurred to me," Tobin said. "I was interested in how cells in the brain signal one another. We were trying to understand how some cells in the brain told other cells to slow down or stop.
"One of the great things about UCLA's College of Letters and Science is that scientists working on basic questions talk with one another and with medical school scientists. At first it wasn't obvious that inhibitory signaling in the brain and in the pancreas uses the same molecules, but they do. The diabetes diagnostic and therapeutic came out of basic research in an unpredictable way.\\\
University of California - Los Angeles
On Sunday, Sept. 17, at a meeting in Copenhagen of the European Association for the Study of Diabetes, Johnny Ludvigsson - pediatrics professor at Sweden's University Hospital, Linköping University - will present results from the phase II study conducted in eight hospitals in Sweden in collaboration with Diamyd Medical (www.diamyd.com), a life science company located in Stockholm, Sweden.
This fundamental discovery that influenced thinking about diabetes was made in the Life Sciences Division of UCLA's College of Letters and Science, said Arthur P. Arnold, UCLA professor and chair of physiological science.
"The broad insight of a basic neuroscience team eventually bore fruit in the fight against this disease," Arnold said. In the 1980s, using newly developed recombinant DNA techniques, Tobin's laboratory was studying genes involved in brain development and function. Tobin's team included graduate student Daniel Kaufman, now a UCLA professor in the department of molecular and medical pharmacology, and graduate student Mark Erlander, now executive vice president and chief scientific officer of AviaraDx, a biotechnology company in Carlsbad, Calif.
Together, Kaufman and Erlander were the first to isolate the genes encoding GAD (glutamic acid decarboxylase) which is an important enzyme because it synthesizes one of the main neurotransmitters for communication between neurons. Tobin's laboratory used these tools to study neuronal development in the brain. What no one knew at that time was that GAD was also made in the cells that made insulin in the pancreas - cells that use the chemical transmitter made by GAD to communicate with other pancreas cells to help control glucose levels in the blood.
A year later, Kaufman's car fortuitously broke down while he was a postdoctoral scholar at the Salk Institute in San Diego, Calif. Forced to wait, he went to the library and stumbled on a report in a medical journal showing a connection between autoimmunity to an unknown protein in insulin-producing cells and diabetes. Kaufman surmised that this unknown protein was in fact GAD, the protein he had studied in Tobin's lab.
To study the possible connection between GAD and diabetes, Kaufman again worked with Tobin and Erlander, using the research tools they had developed to test whether autoantibodies against GAD could be found in frozen blood samples taken from individuals before they developed type 1 diabetes. They found that they could detect autoantibodies against GAD years before the symptoms of diabetes appeared.
In type 1 diabetes, the immune system destroys the insulin-producing cells slowly, over as many as seven years before any symptoms appear, Tobin said. "These tools allowed us to detect the early appearance of an autoimmune reaction more than five years before the onset of diabetes," Tobin said.
Many laboratories throughout the world are now using recombinant GAD to determine whether individuals have autoantibodies to GAD and are likely to develop diabetes. This pre-diagnostic test will be invaluable for preventing diabetes - but first, there must be a therapeutic to slow the progression of the disease.
In his own laboratory at UCLA, Kaufman, along with UCLA's Jide Tian, Michael Clare-Salzler, Eli Sercarz, Paul Lehmann and Tobin, searched for ways to "tolerize" the immune system of diabetes-prone mice to the GAD protein before the autoimmune attack began. The team reported in the journal Nature in 1993 that when young, diabetes-prone mice were treated with a small amount of the GAD protein, their immune systems learned to tolerate the protein. The autoimmune response that leads to type 1 diabetes never developed in these mice as they grew older.
Next, Kaufman and Tian developed the GAD vaccine that was able to inhibit the autoimmune response after it had already begun to attack the insulin producing cells. Kaufman and Tian showed in a study they published in Nature-Medicine in 1996 that, even after the type 1 diabetes disease process had started in diabetes-prone mice, its progression could be inhibited by the GAD vaccine.
The GAD vaccine activated T-cells that recognized GAD, Kaufman and Tian reported. "The T-cells traveled to the pancreas and, recognizing the GAD protein in the insulin-producing cells there, released calming substances called 'anti-inflammatory' cytokines, which suppressed the immune cells that were killing the insulin-producing cells," Tian explained.
UCLA licensed the technology to Diamyd Medical for clinical development. Tobin and Kaufman both serve on the scientific advisory board of Diamyd.
Based on the success of the GAD vaccine to prevent diabetes in mice, Diamyd Medical conducted a phase II clinical trial by treating adults who recently had been diagnosed with diabetes. The results showed that treatment with the GAD vaccine could preserve some insulin production for at least two years after the onset of the disease in adults.
Given these promising results, Diamyd next conducted a larger double-blind clinical trial of the GAD vaccine in 70 children and adolescents who were newly diagnosed with diabetes. After treating new diabetics with the GAD vaccine, or a placebo, the patients were followed for 15 months, without the clinicians knowing which treatment the patients had received. This month Diamyd Medical broke the code and announced that the GAD vaccine demonstrated statistically significant efficacy in preserving insulin production and that no serious adverse events associated with the therapy were observed.
Tobin and Kaufman are optimistic about the drug, which is called Diamyd, but both said it is likely to be at least a few years before a drug for type 1 diabetes is available.
"If the result holds up in a phase III trial, it's going to make a big difference," Tobin said. "It feels terrific."
"It's tremendously gratifying to see our work go from the lab to a clinical application, with the potential to help so many people," Kaufman said. "The data are very strong, and are convincing even to scientists who were initially skeptical. The vaccine is highly targeted; it activates only the immune cells that recognize GAD, which then suppresses the immune cells that are attacking the insulin-producing cells. Most of us who go into science hope our research will advance medical treatment and improve human lives; it's great news."
He added, "Such long-term preservation of insulin production after the onset of diabetes is quite remarkable. Preserving insulin-production is crucial for delaying the complications associated with long-term diabetes, such as kidney and heart disease, and neuropathy. Now that the vaccine has shown efficacy in preserving insulin production after disease onset, we are anxious to see whether the vaccine can also prevent the development of type 1 diabetes."
The children who are likely to develop type 1 diabetes can be identified by screening for autoantibodies to GAD in their blood, Kaufman said. Tobin, 64, is currently managing director of MRSSI, which advises two nonprofit organizations, the High Q Foundation and CHDI, both dedicated to finding therapies for Huntington's disease. From 1975 to 2003, he was on the faculty of UCLA, where he taught introductory biology and neuroscience. He is the coauthor of "Asking About Life," a prize-winning biology textbook whose premise is that questions are more important than answers.
Tobin's research was funded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health. Kaufman's research is funded by the National Institute of Diabetes & Digestive & Kidney Diseases, also part of part of the National Institutes of Health.
Tobin recalls bringing the excitement of his research into the UCLA classes he taught.
"When I taught the introductory biology course, I said here's the standard stuff about the immune system, but let me tell you about something that just happened in my lab," Tobin recalled. "There's a thrill of discovery, and also a sense that there remain challenges ahead; science isn't just learning a set of facts but learning how to approach and formulate scientific problems. That engagement really serves undergraduates at UCLA very differently from undergraduates at non-research colleges."
As is often true in science, solutions to important problems come from unexpected places, and basic research provides the foundation for future applications.
"Type 1 diabetes never occurred to me," Tobin said. "I was interested in how cells in the brain signal one another. We were trying to understand how some cells in the brain told other cells to slow down or stop.
"One of the great things about UCLA's College of Letters and Science is that scientists working on basic questions talk with one another and with medical school scientists. At first it wasn't obvious that inhibitory signaling in the brain and in the pancreas uses the same molecules, but they do. The diabetes diagnostic and therapeutic came out of basic research in an unpredictable way.\\\
University of California - Los Angeles
Neuroscience Current Events and Neuroscience News RSSScientists find molecular trigger that helps prevent aging and disease
Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease?
Can thinking of a loved one reduce your pain?
Yes, according to a new study by UCLA psychologists that underscores the importance of social relationships and staying socially connected.
Shape perception in brain develops by itself
Despite minimal exposure to the regular geometric objects found in developed countries, African tribal people perceive shapes as well as westerners, according to a new study.
Researchers find potential treatment for Huntington's disease
Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfolded proteins associated with Huntington's disease.
New brain findings on dyslexic children
The vast majority of school-aged children can focus on the voice of a teacher amid the cacophony of the typical classroom thanks to a brain that automatically focuses on relevant, predictable and repeating auditory information, according to new research from Northwestern University.
Why can't chimps speak?
If humans are genetically related to chimps, why did our brains develop the innate ability for language and speech while theirs did not?
Neural mechanism reveals why dyslexic brain has trouble distinguishing speech from noise
New research reveals that children with developmental dyslexia have a deficit in a brain mechanism involved in the perception of speech in a noisy environment.
Mouse gene suppresses Alzheimer's plaques and tangles
Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau.
New UAB Study Sheds Light on Brain's Response to Distress, Unexpected Events
In a new study, psychologists at the University of Alabama at Birmingham (UAB) are able to see in detail for the first time how various regions of the human brain respond when people experience an unexpected or traumatic event.
Theory about long and short-term memory questioned by UCL scientists
The long-held theory that our brains use different mechanisms for forming long-term and short-term memories has been challenged by new research from UCL, published today in PNAS.
More Neuroscience Current Events and Neuroscience News Articles
 |
Neuroscience, Fourth Edition by Dale Purves (Author) Neuroscience is a comprehensive textbook created primarily for medical, premedical, and undergraduate students. In a single concise and approachable volume, the text guides students through the challenges and excitement of this rapidly changing field. The book s length and accessibility of its writing are a successful combination that has proven to work equally well for medical students and in undergraduate neuroscience courses. Being both comprehensive and authoritative, the book is also appropriate for graduate and professional use. |
 |
Neuroscience: Exploring the Brain by Mark F Bear (Author), Barry W Connors (Author), Michael A Paradiso (Author) Widely praised for its student-friendly style and exceptional artwork and pedagogy, Neuroscience: Exploring the Brain is a leading undergraduate textbook on the biology of the brain and the systems that underlie behavior. This edition provides increased coverage of taste and smell, circadian rhythms, brain development, and developmental disorders and includes new information on molecular mechanisms and functional brain imaging. Path of Discovery boxes, written by leading researchers, highlight major current discoveries. In addition, readers will be able to assess their knowledge of neuroanatomy with the Illustrated Guide to Human Neuroanatomy, which includes a perforated self-testing workbook. This edition's robust ancillary package includes a bound-in student CD-ROM, an Instructor's... |
 |
Fundamental Neuroscience, Third Edition (Squire,Fundamental Neuroscience) by Larry R. Squire (Editor), Darwin Berg (Editor), Floyd Bloom (Editor), Sascha du Lac (Editor), Anirvan Ghosh (Editor) Fundamental Neuroscience, 3rd Edition introduces graduate and upper-level undergraduate students to the full range of contemporary neuroscience. Addressing instructor and student feedback on the previous edition, all of the chapters are rewritten to make this book more concise and student-friendly than ever before. Each chapter is once again heavily illustrated and provides clinical boxes describing experiments, disorders, and methodological approaches and concepts. A companion web site contains test questions, and an imagebank of the figures for ready use in presentations, slides, and handouts. Capturing the promise and excitement of this fast-moving field, Fundamental Neuroscience, 3rd Edition is the text that students will be able to reference throughout their neuroscience... |
 |
Essential Neuroscience by Allan Siegel (Author), Hreday N Sapru (Author) Essential Neuroscience, Revised First Edition, offers medical and health professions students a concise, clinically relevant text that gives equal weight to the branches of science represented within neuroscience: anatomy, physiology, biology, and chemistry. In this balanced treatment, it distinguishes itself from other competing textbooks. Featuring a unique "building block" approach, Essential Neuroscience, Revised First Edition, now includes the book's fully searchable online text as well as key updates and revisions. |
 |
The Neuroscience of Psychotherapy: Building and Rebuilding the Human Brain by Louis Cozolino (Author) Proposing a reconciliation between neuroscience and psychotherapy. Many forms of psychotherapy, developed in the absence of any understanding of the brain, are now supported by neuroscientific findings. This book argues that the brain is an organ of adaptation, built by interpersonal experiences and capable of change during one's life. Written for anyone interested in the relationship between brain and behavior, it encourages us to consider the brain when attempting to understand others and ourselves. |
 |
The Brain That Changes Itself: Stories of Personal Triumph from the Frontiers of Brain Science (James H. Silberman Books) by Norman Doidge (Author) An astonishing new science called neuroplasticity is overthrowing the centuries-old notion that the human brain is immutable. In this revolutionary look at the brain, psychiatrist and psychoanalyst Norman Doidge, M.D., provides an introduction to both the brilliant scientists championing neuroplasticity and the people whose lives they’ve transformed. From stroke patients learning to speak again to the remarkable case of a woman born with half a brain that rewired itself to work as a whole, The Brain That Changes Itself will permanently alter the way we look at our brains, human nature, and human potential. |
 |
Cognitive Neuroscience: The Biology of the Mind (Third Edition) by Michael S. Gazzaniga (Author), Richard B. Ivry (Author), George R. Mangun (Author) Three leading figures in the field of cognitive neuroscience provide an engaging, narrative driven overview of this path-breaking field. Taking a highly interdisciplinary approach, the authors balance cognitive theory, with neuroscientific and neuropsychological evidence to reveal what we currently know about how the human mind works and to encourage students to think like cognitive neuroscientists. The text has been reorganized to move more seamlessly from micro to macro level topics, and its underlying pedagogy strengthened in order to make it an even more effective teaching tool. Maintaining its commitment to highlight the most cutting-edge trends in the field, the third edition includes the first ever standalone chapter of its kind on social neuroscience.... |
 |
The Student's Guide to Cognitive Neuroscience by Jamie Ward (Author) Reflecting recent changes in the way cognition and the brain are studied, this book provides a comprehensive and student friendly guide to cognitive neuroscience. Following an introduction to neural structure and function, all the key methods and procedures of cognitive neuroscience are explained with a view to helping students understand how they can be used to shed light on the neural basis of cognition. The second part of the book goes on to present an up-to-date overview of the latest theories and findings in all the key topics in cognitive neuroscience, including; vision, attention, memory, speech and language, numeracy, executive function and social and emotional behaviour. Throughout, case studies, newspaper reports and everyday examples are used to provide an easy way in to... |
 |
Neuroscience: Fundamentals for Rehabilitation by Laurie Lundy-Ekman PhD PT (Author) This practical guide focuses on the evidence-based neuroscience information that is most relevant to the practice of physical rehabilitation. It connects the theory of neuroscience with real-world clinical application with such features as: stories written by real people with neurological disorders, case studies, and lists summarizing key features of neurological disorders. It also provides clear descriptions of a complete range of neurological disorders and the body systems they affect. The text progresses logically from the molecular and cellular levels, to systems, and then to regions, to help make complex information easy to master. Special features such as Clinical Notes boxes with "at-a-glance" summaries, Red Flag boxes, and hundreds of full-color illustrations, enhance the learning... |
 |
Theoretical Neuroscience: Computational and Mathematical Modeling of Neural Systems by Peter Dayan (Author), L. F. Abbott (Author) Theoretical neuroscience provides a quantitative basis for describing what nervous systems do, determining how they function, and uncovering the general principles by which they operate. This text introduces the basic mathematical and computational methods of theoretical neuroscience and presents applications in a variety of areas including vision, sensory-motor integration, development, learning, and memory. The book is divided into three parts. Part I discusses the relationship between sensory stimuli and neural responses, focusing on the representation of information by the spiking activity of neurons. Part II discusses the modeling of neurons and neural circuits on the basis of cellular and synaptic biophysics. Part III analyzes the role of plasticity in development... |
| © 2009 BrightSurf.com |